
    
      This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess
      the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult
      subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is
      administered as a subcutaneous (SC) injection. The study is divided into a treatment period
      of 16 weeks and a follow-up period of 8 weeks.
    
  